SAN DIEGO, March 14, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced four poster presentations relating to the company’s pipeline. These presentations will be made at the upcoming ENDO2019, the Annual Meeting of the Endocrine Society, taking place March 23-26, 2019 in New Orleans, Louisiana.
Presentations:
Title: Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
Session: P18. Neuroendocrinology and Pituitary.
Poster: SAT-429.
Date and Time: Saturday, March 23, 1:00-3:00 p.m. CDT
Location: ENDOExpo.
This poster will also be given as a Guided Poster presentation.
Session: Guided Posters: Neuroendocrinology and Pituitary
Poster: GP22.
Date and Time: Saturday, March 23, 1:30-2:00 p.m. CDT
Location: ENDOExpo, Booth 2745
Title: Nonpeptide Orally-Bioavailable ACTH Antagonists: Suppression of ACTH-Induced Corticosterone Secretion and Adrenal Hypertrophy in Rats
Session: P15. Adrenal Basic and Translational Pathways.
Poster: SAT-364.
Date and Time: Saturday, March 23, 1:00-3:00 p.m. CDT
Location: ENDOExpo.
This poster will also be given as a Guided Poster presentation.
Session: Guided Posters: Adrenal (excluding mineralocorticoids)
Poster: GP21.
Date and Time: Saturday, March 23, 1:30-2:00 p.m. CDT
Location: ENDOExpo, Booth 2545
Title: Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-Induced Insulin Secretion in Rats
Session: P07. Novel Aspects of Diabetes and Metabolic Disease Across Tissues and Developmental Stages
Poster: SAT-169.
Date and Time: Saturday, March 23, 1:00-3:00 p.m. CDT
Location: ENDOExpo.
Title: Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Induced Insulin Secretion in Pancreatic Islets from both Rats and Healthy Human Donors
Session: P10. General Pediatric Endocrinology, Autoimmune Polyglandular Syndrome, Obesity, and Metabolic Syndrome
Poster: SAT-260.
Date and Time: Saturday, March 23, 1:00-3:00 p.m. CDT
Location: ENDOExpo.
After the presentations at ENDO2019, the posters will be available on the Crinetics company website at: https://www.crinetics.com/our-approach/
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. Crinetics was founded by a team of scientists with a track record of endocrine drug discovery and development. For more information, please visit www.crinetics.com.
Contacts:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464
Robert H. Uhl
Westwicke Partners
robert.uhl@westwicke.com
(858) 356-5932